Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acuity Pharmaceuticals
Deal signed with Intradigm to develop topical drugs for ophthalmic uses
July 6th, 2005
Acuity Pharmaceuticals announced it has entered into a strategic collaboration with Intradigm Corporation that gives Acuity exclusive rights to Intradigm's leading technology for topical and systemic drug delivery for ophthalmic uses. Acuity and Intradigm also will collaborate to develop topical, and potentially other formulations, of Acuity's lead compound, Cand5. In addition, the agreement exclusively licenses rights to Intradigm's siRNA ophthalmic drug discovery platform and portfolio to Acuity, as well as the intellectual property associated with the ophthalmic drug discovery and delivery programs. "This collaboration with Intradigm provides a...
Source: Biotech Week (2005-07-06)
|
